This is a screaming short opportunity. The FDA will not go against the panel recommendations in what wasn't even a close vote. This is also not an unmet medical need. There are plenty of opioid pain killers without tylenol on the market. The stock will pull back tomorrow.
Don't worry about it !... Biotech Investing 101( Marketable products/Drugs on Late Stages of Development). ...ZGNX already has a revenue generating products on the marketplace. Zohydro just another add-on. Would be nice if it gets an approval, it certainly will be a blockbuster..
Good news based on the following assumptions: If it wanted to reject the drug, the FDA would not require more time. The rejection is an easy vote for "no" and the panel moves on. For any kind of compromise or class REMS program, time is required. Another reason for this delay could be explained simply as well: the FDA could not find the panel of experts they wanted for this decision until a later date. This is a way for the FDA to load the panel with a bias or perhaps to man the panel with experts in the field of testimony of drug abuse, tamper proof technologies, etc....
It is not necessarily bad news, but the notion that an outright rejection vote wasn't to be taken on Friday means that the FDA may be trying to come to terms with these new drug applications for pain relief/management.
....They didn't say no. So there is always a chance, a gliimer albeit small still some optimism as opposed to a flat out no....whoops looks like it is rolling back down now, some day trader is happy this morning.